Active	Status	Sponsor type	Region	Phase	Filter
4 Active 11 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jagannath, Sundar
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma	No Longer Available	N/A		US	Elotuzumab, BMS-901608	Sundar Jagannath, Bristol-Myers Squibb	Multiple Myeloma
Jagannath, Sundar
NCT04052880: Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM	Recruiting	2	18	US	Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib	Larysa Sanchez, Janssen, LP	Newly Diagnosed Multiple Myeloma	12/24	06/25
CaMMouflage, NCT05722418: CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma	Recruiting	1	50	US	CB-011, Cyclophosphamide, Fludarabine	Caribou Biosciences, Inc.	Relapsed/Refractory Multiple Myeloma	02/25	02/27
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma	No Longer Available	N/A		US	Elotuzumab, BMS-901608	Sundar Jagannath, Bristol-Myers Squibb	Multiple Myeloma